https://www.selleckchem.com/products/rvx-208.html
In contradistinction, serum uric acid (SUA) level (SMD -1.80, 95% CI -4.45 to 0.86) (p 0.05) and CRP levels (N = 232; SMD, -0.26; 95% CI, -0.55 to 0.04) (p 0.05) did not improve significantly. The incidence of adverse events (AEs) was not lower in the participants treated with NPDS (N = 750; RR, 0.47; 95% CI, 0.20-1.11) (p 0.05). Conclusion. Current existing evidence is not sufficient to provide clinical guidance regarding the efficacy and safety of NPDS as a treatment for gout due to poor trial quality and lack of standa
Like
Comment
Share
